Stem cell therapy is a type of cell therapy wherein cells are introduced into the damaged tissue so as to treat the disorder or the injury. There are a number of medical researchers who believes that the stem cell therapy has the potential to change the treatment of human diseases and reduce the suffering people face when they have a disease. They believe that there are a lot of potential to replace the damaged and diseased tissues in the body without getting the risk of rejections.

The stem cells have the ability to self-renew and also give rise to further generation of cells that can multiply. There are a number of stem cell therapies that do exist but most of them are still in the experimental stages. The treatments are very costly with an exception of bone marrow transplant. However, researchers believe that one day they will be able to develop technologies from embryonic stem cells and also adult stem cells to cure type I diabetes, cancer, Parkinsons disease, cardiac failure, neurological disorders and many more such ailments.

The stem cell therapy however carries its own pros and cons and like any other therapy it cannot be said that the stem cell therapy is an advantageous package. Here are some of the pros and cons of the therapy.

Pros of the stem cell therapy include:

It offers a lot of medical benefits in the therapeutic sectors of regenerative medicine and cloning.

It shows great potential in the treatment of a number of conditions like Parkinsons disease, spinal cord injuries, Alzheimers disease, schizophrenia, cancer, diabetes and many others.

It helps the researchers know more about the growth of human cells and their development.

In future, the stem cell research can allow the scientists to test a number of potential medicines and drugs without carrying out any test on animals and humans. The drug can be tested on a population of cells directly.

The stem cell therapy also allows researchers to study the developmental stages that cannot be known directly through the human embryo and can be used in the treatment of a number of birth defects, infertility problems and also pregnancy loss. A higher understanding will allow the treatment of the abnormal development in the human body.

The stem cell therapy puts into use the cells of the patients own body and hence the risk of rejection can be reduced because the cells belong to the same human body.

The cons of the stem cell therapy include the following:

The use of the stem cells for research involves the destruction of the blastocytes that are formed from the laboratory fertilization of the human egg.

The long term side effects of the therapy are still unknown.

The disadvantage of adult stem cells is that the cells of a particular origin would generate cells only of that type, like brain cells would generate only brain cells and so on.

If the cells used in the therapy are embryonic then the disadvantage is that the cells will not be from the same human body and there are chances of rejection.

The stem cell therapy is still under the process of research and there are a number of things that needs to be established before it used as a treatment line.

View post:
Pros and Cons of Stem Cell Therapy | HealthGuidance

From the WebMD Archives

If you think your dog or cat has some bad habits, youre not alone. Ten to 15 percent of owners say that they have pet behavior issues, says certified applied animal behaviorist Stephen L. Zawistowski, PhD, science adviser to the ASPCA.

But does your animal need therapy? Yes, if his behavior puts him or others in danger.

Any time the safety or well-being of either the pet or human is in question, a professional should be brought in to determine the best course of action, says certified dog behavior consultant Michael Shikashio. It doesn't have to be as severe as aggression. An animal exhibiting 'quirky' behavior like excessive tail-chasing [could] be suffering from underlying issues.

The first step is seeing your veterinarian. There may be an underlying medical issue that needs to be treated. If you decide to meet with a certified pet behavior professional, be prepared to really work with your animal to get the problem corrected.

A pet owner shouldn't expect a quick fix, Shikashio says.

These are some of the behavior issues common in cats and dogs:

There are several reasons why a pet may become aggressive: He may be protective of his home or family; possessive of his food, bed or toys; fearful; or feel a need to be dominant.

In dogs, signs of aggression include growling, showing the teeth, charging, barking, snarling, snapping, nipping, and biting.

Going for a walk in the neighborhood provides so much stimulation in some dogs that it makes them feel more alert and aggressive. These are dogs that may benefit from "growl" classes, or reactive dog classes.

In these sessions, behaviorists put together two to four dogs in a controlled situation, to teach them social skills, Zawistowski says. The dogs and their owners are under strict supervision and given plenty of space. Each dog is slowly trained to be able to get closer to the other dogs without showing signs of aggression. These classes can help your pooch become more comfortable whenever other dogs or people are around. This will lead to more enjoyable walks for everyone.

An aggressive cat can bite and scratch. He may hiss, growl, howl, stare, flatten his ears, swish his tail or expose his teeth or claws.

Some cats don't like to be petted -- or petted for long periods of time. They may let you know by batting your hand away with a claw. Cats are territorial and may not want certain people or animals in their areas. Mother cats may act aggressively if they think their kittens are threatened. Other cats practice "redirected aggression" -- they may see another cat through a window, and scratch the people or animals that they can reach. Cats that are in pain, for any reason, can be aggressive.

If your cat is showing aggression and you cant figure out why, you should have her checked out by your vet to see if something physical may be causing the behavior. If pain is ruled out, a behaviorist who works with cats may be able to help.

Loud noises, being left alone, or even a change in routine can upset your pet.

Animals can show anxiety in several ways. A dog may pace and pant and whine. A cat may hide or meow. Both can also be destructive: relieving themselves where they shouldnt, and destroying things around the house. Some pets lick themselves so compulsively that their fur comes off and their skin is raw.

Is your dog bored?

Dogs are social animals, Zawistowski says. If you live alone and work long hours, your absence could upset your dog.

Animals who don't have their mental and physical enrichment needs met can display undesirable behaviors, Shikashio says.

If your dog is just bored, increasing walks and spending more time with him may help. But if he is truly afraid when you arent home, you may need to consult with a behaviorist.

Is your cat bothered?

Typical cat behavior issues can include litter box problems and clawing at personal belongings, Shikashio says.

A cat may become upset if you've moved the litter box, changed the litter, or started dating someone new.

Once the root of the problem is discovered, it's easier to address.

If you have a very high-anxiety dog or cat, it's difficult to do behavior modification without [the help of] prescription anxiety medications used to relax the animals, Zawistowski says. The medication can help get the animals comfortable with the behavior changes, and they can later be weaned off, he says.

To find an animal behavior consultant in your area, see the International Association of Animal Behavior Consultants (iiabc.org) or American College of Veterinary Behaviorists (dacvb.org).

SOURCES:

Michael Shikashio, certified dog behavior consultant, Connecticut; president, International Association of Animal Behavior Consultants.

Stephen L. Zawistowski, PhD, certified applied animal behaviorist, New York; science adviser, American Society for the Prevention of Cruelty to Animals.

International Association of Animal Behavior Consultants: Find an Animal Behavior Consultant.

American College of Veterinary Behaviorists: Member Directory.

Pagination

See the rest here:
Deciding if Animal Behavior Therapy Is Right for ... - WebMD

A PET scan is a nuclear medicine imaging test. It uses a form of radioactive sugar to create 3D colour images to see how your bodys cells are working.

PET uses a radioactive material (radiopharmaceutical) made up of a radioactive isotope that is attached to a material used in the body, usually sugar (glucose). It travels through the body and gathers in cells that are using a lot of energy, such as cancer cells. The radioactive material gives off tiny positively charged particles (positrons). A camera records the positrons and turns the recording into pictures on a computer.

A PET scan may be done to:

Combined PET-CT scanning joins a PET scan and a computed tomography (CT) scan into one test. It may provide a more complete image of a tumours location, growth or spread than either test alone.

Before you have any nuclear medicine test, it is important to tell the nuclear staff if you are breastfeeding or pregnant or think you may be pregnant.

Tell the nuclear medicine staff if you have diabetes. They may ask you to adjust your normal dose of diabetes medicine.

Before the scan, you may be told to:

You may be told to not wear clothes with metal zippers, belts or buttons on the day of the scan. Or you may change into a gown for the test. If you are wearing glasses, jewellery or objects that could interfere with the test, you will be asked to take them off.

Check with the nuclear medicine department to see if there is anything else you need to do before the test.

A PET scan is usually done as an outpatient procedure in the nuclear medicine department of a hospital or specialized PET scan centre. This means that you dont stay overnight. The test takes 45 minutes to 2 hours, depending on whether a single organ or the whole body is scanned.

The nuclear medicine staff will ask you if youve recently had surgery, a biopsy or cancer therapy (such as chemotherapy or radiation therapy). They may also check your blood sugar level before the test.

The radioactive material is injected into a vein in your hand or arm. It needs about 1 hour to travel throughout your body and get absorbed by the cells.

You will be asked to urinate just before the scan. Depending on the area being studied, a urinary bladder catheter or medicine (diuretic) may be used to help get rid of urine.

For the scan, you will sit or lie down on the exam table and will be asked to stay very still. The exam table moves through the PET scanner, which is shaped like a large doughnut. Detectors in the scanner pick up the signal from the radioactive material in the body. A computer analyzes the patterns and creates 3D colour images of the area being scanned.

If youre having a PET-CT scan, you will have one scan after the other during the same hospital visit.

The radioactive material passes out of the body through urine or stool (feces). It may take a few hours or days to completely pass out of the body. Drink lots of fluids after the test to help flush it out.

The dose of x-rays or radioactive materials used in nuclear medicine imaging can be different for every test. The dose depends on the type of procedure and body part being examined. In general, the dose of radioactive material given during a PET scan is small and you are exposed to low levels of radiation during the test. The benefits of having a PET scan outweigh the risk of exposure to the small amount of radiation received during the scan.

Allergic reactions to the radioactive material may occur, but they are extremely rare.

PET scans detect areas of activity (like cell growth) in the body. More radioactive material collects in cancer cells than normal cells and will appear brighter on the image.

Not all cancers show up on a PET scan. PET scan results are often used with other imaging and lab test results. Other tests are often needed to find out whether an area that collected a lot of radioactive material is non-cancerous (benign) or cancerous (malignant). Recent surgery, chemotherapy and radiation therapy and some medicines may affect the test results.

Your doctor may recommend more tests, procedures, follow-up care or treatment.

Preparing children before a test or procedure can help lower their anxiety, increase their cooperation and develop their coping skills. This includes explaining to children what will happen during the test, such as what they will see, feel and hear.

Preparing a child for a PET scan depends on the age and experience of the child. Find out more about helping your child cope with tests and treatments.

See the article here:
Positron emission tomography (PET) scan - cancer.ca

What is StemEnhance Ultra?

StemEnhance Ultra concentrates and combines extracts from natures most primitive superfoods, fresh watermicroalgae and marine macroalgae, proving the body with the ultimate in stem cell support.

StemEnhance Ultra assists the bodys inherent ability for long-term self-renewal by supporting the bodys natural release ofbone marrowstem cells.

StemEnhance Ultra provides the ultimate in stem cell support. It contains a proprietary blend of highly concentrated extracts, including Fucoidan and Cerules exclusive patented ingredients StemEnhance (AFA concentrate) & Mesenkine.

StemEnhance Ultra (AFA concentrate) is shown in studies to support the release of stem cells from the bone marrow.

Fucoidan (undaria pinnatifida) is a marinealgaewell known to support the immune system. Cerules fucoidan comes from undaria harvested from pristine environments like the Tasman Sea and Patagonia. Fucoidan from Undaria Pinnatifida has been documented to increase the number of circulatingstem cells.

Mesenkine is a unique extract from Spirulina, isolated through Cerules patented extraction process, that supports the release and homing of stem cells by balancing key messengers involved in stem cell function.

StemEnhance Ultra does not contain dairy, wheat, gluten, peanut, soy, corn, or allergens. There are no artificial flavors or colors. It is 100% vegetarian, non-GMO, and free from herbicides and pesticides.

The primary roles of adult stem cells in a living organism are to maintain and repair the tissue in which they are found. Stem cells released from the bone marrow can migrate to various tissues where they contribute to the process of tissue repair.

Suggested usage is 2 capsules 1 to 2 times daily.

The clinical studies were done using adults therefore we recommend StemEnhance Ultra for adult consumption, however there are no known contraindications for children.

StemEnhance Ultra is formulated for human consumption. We know of no reason that it may be harmful to pets. AFA and spirulina have been used in the pet nutrition industry for years. However, no studies have been done using the product for pet consumption. Please consult with your Veterinarian.

StemEnhance Ultra is the result of 16 years of research and constitutes the most efficacious and scientifically provenstem cell nutritionproduct on the market.

Through multiple clinical trials, StemEnhance Ultra was documented to optimize stem cell function in the body by increasing the number of bothstem cellsand and Endothelial Progenitor Cells (EPCs) in the bloodstream, supporting optimum renewal and repair of tissues and organs.

StemEnhance Ultra also contains Mesenkine, that was shown to increase the blood concentration of G-CSF that plays a key role in stem cell release.

See StemEnhance research here.

As stated on the label, the vegetarian capsule is made from hypromellose. Hypromellose is cellulose derivative or plant fiber.

StemEnhance Ultra ingredients are certified Kosher.It is not certified Halal.

There is an expiration date at the bottom of each bottle. StemEnhance Ultra has a shelf life of 3 years from date of manufacture. All bottles should be stored in a cool, dry place.

Yes! The Cerule products can be consumed together and were designed to enhance the beneficial effects of each other. We know of no concerning interaction between the Cerule products and other nutritional supplements.

Like many green foods, StemEnhance Ultra contains naturally occurring vitamin K, which could interfere with vitamin K blockers used to thin the blood, such as coumadin.

If you have any health condition and/or are using medication, then consult your attending health care provider before consuming any nutritional supplement.

For some people, due to their conditions and medications, they need to manage their intake of certain nutrients. Below are the amounts of naturally occurring nutrients found in the plant based ingredients within StemEnhance Ultra:

Vitamin K: around 20 ug per serving (2 capsules)Iron: 0.34 mg per serving (2 capsules)Iodine: around 4 ug per serving (2 capsules)Sodium: 9.66 mg per serving (2 capsules)PEA: >0.5%

Pregnancy and nursing are considered special conditions. We recommend that your attending Doctor(s) be made aware of any and all supplements consumed during this time. At this time, we do not advise StemEnhance Ultra consumption during pregnancy.

Go here to read the rest:
StemEnhance Ultra: The Best Stem Cell Supplement - Our ...

Active Comparator: Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd

Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.

Bortezomib 1.3 mg/m^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Other Name: Velcade

Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Other Name: Revlimid

Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.

Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.

Bortezomib 1.3 mg/m^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Other Name: Velcade

Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Other Name: Revlimid

Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

View original post here:A Study Comparing Daratumumab, VELCADE (Bortezomib ...

See the article here:
Pet Stem Cell Therapy

To our knowledge, The Institute is the first of its kind in the United States and it will primarily be housed here at Saint Francis Pet Care Center. Patients will experience the kind and thorough care that many of you have already come to know. Donations and grants received by our non-profit 501c3 Vets for Pets will be utilized to promote awareness and educate pet parents about Stem Cell Therapy. We will continue to collaborate with both veterinary and human researchers to assist with FDA approval and development of the most effective treatment protocols.

As I pour over the research, the possibilities of treatment are almost limitless. At this point, our treatment will be relegated to dogs, but we anticipate the ability to treat other species soon. Please click here to see what current and upcoming studies we are conducting. For patients who do not qualify for a study, we will have the ability to still employ stem cell therapy on an individual basis. If you would like to learn more about stem cell therapy in pets, please click the link to view Stem Cells 101.

For further inquiry, please feel free to contact us.

See the original post here:
About Us - The Pet Stem Cell Institute

Background

Pre-transplantation 18F-fluorodeoxyglucose (FDG) PET-negativity is one of the strongest predictors of outcome after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) for patients with relapsed or refractory Hodgkin's lymphoma. In this study, we assessed the feasibility and activity of PET-adapted salvage therapy with brentuximab vedotin, followed by augmented ifosfamide, carboplatin, and etoposide (ICE).

In this non-randomised, open-label, single-centre, phase 2 trial, we enrolled patients with relapsed or refractory Hodgkin's lymphoma who had failed one previous doxorubicin-containing chemotherapy regimen. All patients received weekly infusions of 12 mg/kg brentuximab vedotin on days 1, 8, and 15 for two 28 day cycles. After completion of brentuximab vedotin treatment, patients received a PET scan. Patients who achieved PET-negative status (a Deauville score of 1 or 2) proceeded directly to HDT/ASCT; those with persistent abnormalities on PET received two cycles of augmented ICE (augICE; two doses of ifosfamide 5000 mg/m2 in combination with mesna 5000 mg/m2 continuous infusion over 24 h, days 1 and 2; one dose of carboplatin AUC 5, day 3; three doses of etoposide 200 mg/m2 every 12 h, day 1) before consideration for HDT/ASCT. Only patients with persistent abnormalities on PET after brentuximab vedotin received augICE; however, all patients in the intention-to-treat population were assessed for the primary outcome, which was the proportion of patients who were PET-negative after brentuximab vedotin alone or brentuximab vedotin followed by augICE. This study is registered with ClinicalTrials.gov, number NCT01508312, and is no longer accruing patients.

Between Jan 5, 2012, and Oct 4, 2013, we enrolled 46 patients. One patient was deemed ineligible, and not evaluable, before treatment initiation owing to having nodular, lymphocyte-predominant Hodgkin's lymphoma and thus 45 patients received treatment. After brentuximab vedotin, 12 patients (27%, 95% CI 1340) were PET-negative and proceeded to HDT/ASCT. 33 (73%, 95% CI 6086) patients were PET-positive after brentuximab vedotin; one PET-positive patient withdrew consent, therefore 32 PET-positive patients received augICE, 22 (69%, 95% CI 5385) of whom were PET-negative. Overall, 34 patients (76%, 95% CI 6289) achieved PET-negativity. All 44 patients who completed treatment as per protocol proceeded to receive HDT/ASCT. Brentuximab vedotin was well tolerated and associated with few grade 34 adverse events including hyperglycaemia (two [4%] patients, grade 3), nausea (one [2%], grade 3), hypoglycaemia (one [2%], grade 3 and one [2%], grade 4), and hypocalcaemia (one [2%], grade 3 and one [2%], grade 4).

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augICE resulted in a high proportion of patients with relapsed or refractory Hodgkin's lymphoma achieving PET-negativity, and therefore could optimise the chance of cure after HDT/ASCT.

See more here:
PET-adapted sequential salvage therapy with brentuximab ...

Veterinary healthcare from your pets point of view

Clickbelow towatch our 2-minute video where Dr. Chris Lee explains our unique philosophy:

Pet Universe Vet Adelaide is a family-run veterinary clinic that has been operating for over 10 years in Adelaides northern suburbs. We offer a range of services to improve your pets health and wellness including:

Our vet centre is friendly, caring and professional, helping to ease your pets fears and your own. On top of excellent veterinary care, we also provide relaxing background music, gentle handling, an optimum pain-relief policy and lots of treats & fuss!

Pets can fall sick at any time. So to offer quality care, our Broadview veterinary clinic is now available for appointments 7 days a week. You can book with me or any of my associates at Broadview or at our Northgate vet practice (open 6 days a week). Contact us at Pet Universe when you need a trusted vet Adelaide.

The rest is here:
Vet Adelaide | Quality Veterinary Healthcare | Pet Universe

At Cell Therapy Sciences we harness the regenerative properties of mesenchymal stem cells to prepare clinical therapies for dogs and horses. Based on our own research, we have optimised these therapies to ensure you receive the very best cells for your patients.

From a small piece of an animal's own tissue, many millions of regenerative cells can be grown by culture-expansion in our specialised VMD-authorised laboratory. We have developed our own, evidence-based procedures for harvest, implantation and transportation, which are simple and practical for vets - and ensure the highest possible standards of safety and quality for pets.

The Evidence Base?

Culture-expanded, mesenchymal stem cells (MSCs) have been used to treat lameness, pain and degenerative joint problems in dogs and horses for more than 10 years. The most recent clinical evidence includes a number of significant, well controlled and large clinical investigations into canine OA (e.g. Shah et al 2018; Harman et al 2016) with authors reporting that MSCs can not only reduce pain and inflammation, but also improve quality of life and enhance tissue repair. The World Small Animal Veterinary Association recognises stem cells in their pain management protocol and include stem cell injectionsfor DJD in dogs and cats in their Pain Council Guidelines.

Why use our culture-expanded stem cells?

We are the most experienced companion animal stem cell laboratory in the UK, having prepared > 2,000 stem cell treatments for intra-articular and intravenous use in client-owned dogs and cats.

We conduct our own laboratory research and have ongoing scientific collaborations with leading stem cell centres, including University College London, Stem Cells Scotland and Coventry University.

Four clinical investigations to date in moderate to severe canine OA have reported significant reductions in pain and improvements in functional mobility following intra-articular injections using our stem cell preparations. These include the first reported study to use two validated arthritis questionnaires to evaluate clinical outcomes in OA (Armitage et al 2018).

Our VMD-authorised cryogenic storage and transport system maximises stem cell quality and viability at point of care and has been shown to be superior to shipping at ambient temperatures.

See the original post here:
Cell Therapy Sciences

Active Comparator: Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd

Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.

Bortezomib 1.3 mg/m^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Other Name: Velcade

Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Other Name: Revlimid

Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.

Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.

Bortezomib 1.3 mg/m^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Other Name: Velcade

Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Other Name: Revlimid

Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

View original post here:
A Study Comparing Daratumumab, VELCADE (Bortezomib ...